Your browser doesn't support javascript.
loading
Matchmaker, matchmaker make me a match: Opportunities and challenges in optimizing compatibility of HLA eplets in transplantation.
Lemieux, William; Mohammadhassanzadeh, Hossein; Klement, William; Daniel, Claude; Sapir-Pichhadze, Ruth.
Affiliation
  • Lemieux W; Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC, Canada.
  • Mohammadhassanzadeh H; Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC, Canada.
  • Klement W; Centre for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre, Montréal, QC, Canada.
  • Daniel C; Canadian Blood Services, Ottawa, Ontario, Canada.
  • Sapir-Pichhadze R; Division of Hematology, McGill University Health Centre, Montréal, QC, Canada.
Int J Immunogenet ; 48(2): 135-144, 2021 Apr.
Article de En | MEDLINE | ID: mdl-33426788
ABSTRACT
The development of donor-specific antibodies (DSAs) is a major complication in transplantation, which is associated with inferior graft survival, impaired quality of life, and increased healthcare costs. DSA develop upon recognition of nonself HLA by the recipient's immune system. HLA molecules contain epitopes, which are the surface regions of HLA molecules recognized by antibodies. HLAMatchmaker is an algorithm for assessing donorrecipient HLA compatibility at the level of structurally defined HLA targets called eplets. The consideration of eplets, rather than the whole HLA molecule, could offer some advantages when classifying the immune risk associated with particular donorrecipient pairs. Assessing compatibility at the level of HLA eplets could decrease misclassification of post-transplant immune risk by improving specificity, when antibodies are confirmed to be directed against donor eplets missing from the recipient's repertoire of eplets. Consideration of eplets may also increase the sensitivity of immune risk assessment, when identifying mismatched eplets that could give rise to new, not previously detected, donor-specific antibodies post-transplant. Eplet matching can serve as a rational strategy for immune risk mitigation. Herein, we review the evolution of HLA (in) compatibility assessment for organ allocation. We outline challenges in the implementation of eplet-based donorrecipient matching, including unavailability of allele-level donor genotypes for 11 HLA loci at the time of organ allocation and difficulty in assessing the hierarchy of immune risk associated with particular HLA eplet mismatches. Opportunities to address some of the current shortcomings of donor genotyping and HLAMatchmaker are also discussed. While there is a demonstrated benefit in the application of HLAMatchmaker for donor recipient HLA (in)compatibility assessment, evolving long-read genotyping methods, compilation of large data sets with allele-level genotypes, and standardization of methods to verify eplets as determinants of immune-mediated injuries are required before HLA eplet matching is implemented in organ allocation to improve upon transplant outcomes.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Logiciel / Histocompatibilité / Antigènes HLA / Épitopes Type d'étude: Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Int J Immunogenet Sujet du journal: ALERGIA E IMUNOLOGIA / GENETICA Année: 2021 Type de document: Article Pays d'affiliation: Canada

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Logiciel / Histocompatibilité / Antigènes HLA / Épitopes Type d'étude: Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Int J Immunogenet Sujet du journal: ALERGIA E IMUNOLOGIA / GENETICA Année: 2021 Type de document: Article Pays d'affiliation: Canada